ArticleEye and vision (London, England)2026
Dual-surface aberration-increasing lenses versus single-vision lenses in non-myopic children: a randomized clinical trial.
Article in Eye and vision (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo investigate the 1-year preventive efficacy of dual-surface aberration-increasing (DSAI) lenses on axial elongation and refractive change in non-myopic children.
methodsThis was a 2-year randomized, controlled, prospective trial with a planned interim analysis at the 1-year follow-up to assess the preliminary efficacy and safety of DSAI lenses. One hundred children aged 6-12 years with cycloplegic spherical equivalent refraction between -0.50 diopters (D) and + 2.00 D, classified as non-myopic, were recruited. Participants were randomly assigned to wear either DSAI spectacle lenses or single-vision (SV) spectacle lenses in daily life. The primary outcomes were axial elongation and refractive change relative to baseline measurements, with axial elongation considered the main structural outcome in the results.
resultsEnrolment commenced in June 2023. One hundred participants were recruited, and 92 (DSAI group: n = 46, mean ± standard deviation age: 8.15 ± 1.49 years; SV group: n = 46, 8.32 ± 1.62 years) completed the 1-year follow-up. No intervention-related adverse events were observed during the study period. Participants in the DSAI group exhibited significantly less axial elongation (difference: 0.15 mm; 95% confidence interval [CI]: 0.06 to 0.24 mm; P = 0.002) and refractive change (difference: -0.26 D; 95% CI: -0.50 to -0.02 D; P = 0.032) than those in the SV group. Subgroup analysis showed that emmetropic children, older children (8.1-12.0 years), and those wearing lenses for longer durations (≥ 11 h/day) in the DSAI group had significantly less model-adjusted axial elongation than the corresponding SV subgroups (all P < 0.05).
conclusionThe 1-year interim results suggest that DSAI lenses help to slow axial elongation and refractive change in non-myopic children, with a relatively greater effect observed in emmetropic children, older children, and those who wore the lenses for longer durations.
trial registrationThis trial is registered at Chinese Clinical Trial Registry with trial registration number: ChiCTR2300078464.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.